Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 12/20 | 0.40 |
| ▸ | CA1 | P00915 | 12/20 | 0.40 |
| ▸ | CA2 | P00918 | 12/20 | 0.40 |
| ▸ | CA4 | P22748 | 5/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 2/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6679535 | 1.00 | KDM4E (0.42) | KDM4EALDH1A1ALOX15HSD17B10TP53 | |
| SCHEMBL6679253 | 0.96 | KDM4E (0.42) | KDM4EALDH1A1ALOX15HSD17B10TP53 | |
| SCHEMBL6679254 | 0.96 | KDM4E (0.42) | KDM4EALDH1A1ALOX15HSD17B10TP53 | |
| SCHEMBL6687820 | 0.94 | TP53 (0.40) | TP53CA12CA1CA2CA4 | |
| SCHEMBL6687821 | 0.94 | TP53 (0.40) | TP53CA12CA1CA2CA4 | |
| SCHEMBL6803249 | 0.90 | TP53 (0.40) | KDM4EALDH1A1ALOX15HSD17B10TP53 | |
| SCHEMBL6541193 | 0.90 | TP53 (0.51) | TP53CA12CA1CA2CA4 | |
| SCHEMBL6541200 | 0.90 | TP53 (0.51) | TP53CA12CA1CA2CA4 | |
| SCHEMBL6681944 | 0.90 | KDM4E (0.41) | KDM4EALDH1A1ALOX15HSD17B10TP53 | |
| SCHEMBL6681941 | 0.90 | KDM4E (0.41) | KDM4EALDH1A1ALOX15HSD17B10TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| WO-2004045610-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FANCD2, FANCI, HRH2 | KDM4E 994/4885ALDH1A1 168/4885ALOX15 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.